{
    "clinical_study": {
        "@rank": "21789", 
        "arm_group": {
            "arm_group_label": "Exemestane plus Everolimus", 
            "arm_group_type": "Experimental", 
            "description": "Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether exemestane plus everolimus are effective\n      in the treatment of patients who have achieved disease stabilization after induction\n      chemotherapy for hormone-receptor positive metastatic breast cancer."
        }, 
        "brief_title": "Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer", 
        "condition": "Hormone Receptor Positive Malignant Neoplasm of Breast", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving\n      clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or\n      symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus\n      exemestane."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal women as defined in the protocol page 9;\n\n          -  Histologically and/or cytologically confirmed invasive breast cancer with stage IV\n             disease according to AJCC;\n\n          -  Confirmed ER/PR-positive, and HER-2 negative tumor;\n\n          -  Disease progression on or following prior endocrine therapy with tamoxifen or\n             non-steroidal aromatase inhibitor, as defined in protocol, prior to standard of care\n             (SOC) induction chemotherapy\n\n          -  Patient with documented evidence of visceral disease  (including but not limited to\n             hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or\n             symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization\n             after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor\n             assessments;\n\n          -  ECOG performance status \u2264 2 or Karnofsky performance status \u2265 50% prior to the start\n             of study treatment;\n\n          -  Adequate organ function prior to the start of study treatment as defined in the\n             protocol;\n\n          -  Able to swallow and retain oral medication;\n\n          -  Able to give written informed consent;\n\n        Exclusion Criteria:\n\n          -  Male patient;\n\n          -  Metastatic disease limited to the bone or soft tissues only and with no history of\n             other visceral metastases;\n\n          -  History of brain or other CNS metastases;\n\n          -  Previous treatment with exemestane, unless exemestane was administered in the\n             adjuvant setting and stopped >1 year before metastatic relapse;\n\n          -  Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease\n             according to AJCC - or - treated with SOC chemotherapy for invasive breast cancer\n             with stage IV disease according to AJCC without clinical benefit;\n\n          -  History of neurological or psychiatric disorders;\n\n          -  Any serious cardiovascular diseases in the previous 6 months;\n\n          -  Impairment of gastrointestinal function or gastrointestinal disease;\n\n          -  Patients with uncontrolled infection;\n\n          -  Patients with an active, bleeding diathesis or on oral anti-vitamin K medication\n             (except low dose coumadin defined as 1 mg a day);\n\n          -  Chronic treatment with systemic steroids or another immunosuppressive agent;\n\n          -  Patients with a pre-existing peripheral neuropathy > grade 1;\n\n          -  Patients who are hepatitis B and/or hepatitis C carriers;\n\n          -  Known human immunodeficiency virus infection;\n\n          -  Prior exposure to mTOR inhibitors;\n\n          -  Hypersensitivity to rapamycin or other similar compounds;\n\n          -  Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP\n             will not be included in this study;\n\n          -  Prior treatment with any investigational agent within the preceding 4 weeks;\n\n          -  Other conditions in the judgment of the investigator, would make the patient\n             inappropriate for entry into this study.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02025712", 
            "org_study_id": "M004/EXE-EVE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exemestane plus Everolimus", 
                "description": "Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.", 
                "intervention_name": "Exemestane", 
                "intervention_type": "Drug", 
                "other_name": "Aromasin"
            }, 
            {
                "arm_group_label": "Exemestane plus Everolimus", 
                "description": "Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Afinitor, RAD001"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Exemestane", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 29, 2013", 
        "location": {
            "contact": {
                "last_name": "Louis Chow", 
                "phone": "(852)28610286"
            }, 
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "China"
                }, 
                "name": "Unimed Medical Institute"
            }, 
            "investigator": {
                "last_name": "Louis Chow", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer", 
        "overall_contact": {
            "last_name": "Louis Chow, MD", 
            "phone": "(852)28610286"
        }, 
        "overall_official": {
            "affiliation": "Organisation for Oncology and Translational Research", 
            "last_name": "Louis Chow", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as from date of treatment initiation with everolimus plus exemestane to the date of progression or death if no documented disease progression", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks in the first 24 weeks of treatment and every 12 weeks thereafter, up to 8 months (estimated)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02025712"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks, up to 8 months (estimated)"
            }, 
            {
                "measure": "Clinical benefit rate", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks, up to 8 months (estimated)"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "date of treatment initiation with everolimus plus exemestane until the date of death, censored at the last date known alive,  whichever came first, assessed up to 32 months"
            }, 
            {
                "measure": "Incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Continuous during the study, up to 28 days after the last treatment"
            }
        ], 
        "source": "Organisation for Oncology and Translational Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Organisation for Oncology and Translational Research", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}